Yilmaz Ozge, Sogut Ayhan, Kose Umit, Sakinci Ozcan, Yuksel Hasan
Dept. of Pediatric Allergy and Pulmonology, Celal Bayar University Medical Faculty, Manisa, Turkey.
J Asthma. 2009 Mar;46(2):191-3. doi: 10.1080/02770900802604137.
Efficacy of bronchodilator treatment in children with asthma depends on the proper use of inhalation devices. The aim of this study was to compare the efficacy of inhaled bronchodilator treatment with a spacer and a nebulizer in children with acute asthma findings.
Fifty-eight children with acute asthma findings who received ambulatory inhaled bronchodilator treatment with a nebulizer and 39 with a spacer were enrolled in the study. Duration of asthma, inhaled steroid treatment and the number of exacerbations during the previous year were recorded. Duration of current acute symptoms, exacerbation severity score and duration of respiratory findings after initiation of treatment were also recorded.
Children in both groups were similar in age (76.5 +/- 30.3 months using a nebulizer vs 83.1 +/- 25.1 in spacer group, p = 0.26). Duration after diagnosis of asthma, initiation of inhaled steroid treatment and exacerbation symptoms were similar between groups (p = 0.15, 0.76 and 0.93, respectively). Exacerbation severity score in the nebulizer group was not significantly different from the spacer group (2.6 +/- 0.7 vs 2.8 +/- 0.7 respectively, p = 0.19). Number of exacerbations in the previous year was not different (2.0 +/- 1.2 in the nebulizer group vs 1.6 +/- 0.9 in the spacer group, p = 0.08). Duration of acute asthma findings after initiation of inhaled bronchodilator treatment was similar between the two groups (6.5 +/- 2.9 vs 7.2 +/- 4.6 p = 0.34).
Nebulizers and spacers have similar influence on the duration of acute asthma findings in children when used in ambulatory home bronchodilator treatment.
支气管扩张剂治疗哮喘患儿的疗效取决于吸入装置的正确使用。本研究旨在比较雾化器和储物罐吸入支气管扩张剂治疗急性哮喘患儿的疗效。
本研究纳入了58例接受门诊雾化器吸入支气管扩张剂治疗的急性哮喘患儿和39例接受储物罐吸入治疗的患儿。记录哮喘病程、吸入糖皮质激素治疗情况以及前一年的急性发作次数。同时记录当前急性症状的持续时间、急性发作严重程度评分以及治疗开始后呼吸症状的持续时间。
两组患儿年龄相似（雾化器组为76.5±30.3个月，储物罐组为83.1±25.1个月，p = 0.26）。两组间哮喘诊断后的病程、吸入糖皮质激素治疗的起始时间以及急性发作症状相似（p分别为0.15、0.76和0.93）。雾化器组的急性发作严重程度评分与储物罐组无显著差异（分别为2.6±0.7和2.8±0.7，p = 0.19）。前一年的急性发作次数也无差异（雾化器组为2.0±1.2次，储物罐组为1.6±0.9次，p = 0.08）。吸入支气管扩张剂治疗开始后，两组急性哮喘症状的持续时间相似（6.5±2.9天与7.2±4.6天，p = 0.34）。
在门诊家庭支气管扩张剂治疗中，雾化器和储物罐对儿童急性哮喘症状持续时间的影响相似。
